Cargando…
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fai...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488186/ https://www.ncbi.nlm.nih.gov/pubmed/33060168 http://dx.doi.org/10.1183/16000617.0269-2020 |
_version_ | 1784792605009117184 |
---|---|
author | Platé, Manuela Guillotin, Delphine Chambers, Rachel C |
author_facet | Platé, Manuela Guillotin, Delphine Chambers, Rachel C |
author_sort | Platé, Manuela |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fail to halt disease progression and have significant side-effect profiles. Therefore, there remains a pressing need to develop novel therapeutic strategies for IPF. Mammalian target of rapamycin (mTOR) forms the catalytic subunit of two complexes, mTORC1 and mTORC2. mTORC1 acts as critical cellular sensor which integrates intracellular and extracellular signals to reciprocally regulate a variety of anabolic and catabolic processes. The emerging evidence for a critical role for mTORC1 in influencing extracellular matrix production, metabolism, autophagy and senescence in the setting of IPF highlights this axis as a novel therapeutic target with the potential to impact multiple IPF pathomechanisms. |
format | Online Article Text |
id | pubmed-9488186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94881862022-11-14 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Platé, Manuela Guillotin, Delphine Chambers, Rachel C Eur Respir Rev Mini Review Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fail to halt disease progression and have significant side-effect profiles. Therefore, there remains a pressing need to develop novel therapeutic strategies for IPF. Mammalian target of rapamycin (mTOR) forms the catalytic subunit of two complexes, mTORC1 and mTORC2. mTORC1 acts as critical cellular sensor which integrates intracellular and extracellular signals to reciprocally regulate a variety of anabolic and catabolic processes. The emerging evidence for a critical role for mTORC1 in influencing extracellular matrix production, metabolism, autophagy and senescence in the setting of IPF highlights this axis as a novel therapeutic target with the potential to impact multiple IPF pathomechanisms. European Respiratory Society 2020-10-15 /pmc/articles/PMC9488186/ /pubmed/33060168 http://dx.doi.org/10.1183/16000617.0269-2020 Text en Copyright ©ERS 2020. https://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Mini Review Platé, Manuela Guillotin, Delphine Chambers, Rachel C The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis |
title | The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis |
title_full | The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis |
title_fullStr | The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis |
title_full_unstemmed | The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis |
title_short | The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis |
title_sort | promise of mtor as a therapeutic target pathway in idiopathic pulmonary fibrosis |
topic | Mini Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488186/ https://www.ncbi.nlm.nih.gov/pubmed/33060168 http://dx.doi.org/10.1183/16000617.0269-2020 |
work_keys_str_mv | AT platemanuela thepromiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis AT guillotindelphine thepromiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis AT chambersrachelc thepromiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis AT platemanuela promiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis AT guillotindelphine promiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis AT chambersrachelc promiseofmtorasatherapeutictargetpathwayinidiopathicpulmonaryfibrosis |